Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk B : Novo Nordisk reaches a milestone in animal testing (VIDEO) (28 November 2011)

share with twitter share with LinkedIn share with facebook
share via e-mail
11/28/2011 | 09:11am EDT

As of 28 November 2011, Novo Nordisk will no longer use living animals to test the quality of the batches of medicine coming out of Novo Nordisk's production lines. These tests have for years been required by health authorities as part of their approval of the products.

"Today's achievement is a milestone in our ongoing commitment to animal ethics in Novo Nordisk. We have been working for more than a decade, in close collaboration with regulatory authorities around the world, to eliminate obsolete tests or develop and certify new laboratory assays that can be used instead of animals to evaluate the consistent quality of our marketed products," says Executive Vice President and Chief Science Officer, Mads Krogsgaard Thomsen.

Novo Nordisk has a commitment to the 3R principles to 'Reduce', 'Refine' or 'Replace' the use of animal testing within the pharmaceutical industry. Therefore, a task force was established more than ten years ago with the ambitious aim to eliminate all redundant  product control tests in living animals or replace them with other test methods that would guarantee the same product safety.

Live animals that have been used in these biological product control tests include mice, rats, guinea pigs, hamsters and rabbits. Over the years, the number of animals used in this area has been gradually reduced from more than 13,000 animals a year in the 90s, to 2,078 animals in 2000 and to 772 animals in 2010. The last living animals are used for a virus control on 28 November 2011, and in 2012 the number of biological product control tests performed on living animals will be zero.

In the 90s Novo Nordisk reduced the total number of animals used by almost 70%. Since then Novo Nordisk has been able to keep the numbers at approximately the same level despite increasing research activities year on year.

In 2010, the number of animals used in Novo Nordisk was 62,152. At present, some experiments on living animals are essential for all pharmaceutical companies in the processes of discovery and development of new pharmaceuticals. It is in addition a requirement from the authorities that drug candidates are tested in living animals before they can be tested in humans.

See the video "A milestone in animal ethics" (duration 9 mins)

For more information, please contact:
Mette Kruse Danielsen
Media Relations Manager
Tel +45 3079 3883
email: mkd@novonordisk.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK AS
08/20AstraZeneca diabetes drug shows promise in heart failure
08/19NOVO NORDISK A/S : - Securities lawsuit filed in Denmark against Novo Nordisk
08/19NOVO NORDISK : Disclosure of transaction data
08/19NOVO NORDISK : A/S – Share repurchase programme
08/16NOVO NORDISK : contests Danish lawsuit claiming $1.75 billion
08/16NOVO NORDISK A/S : Securities lawsuit filed in Denmark against Novo Nordisk
08/16NOVO NORDISK AS : Ex-dividend day for interim dividend
08/12United States Insulin Delivery Devices Market is Anticipated to Reach US$ 6 B..
08/12NOVO NORDISK A/S : - Share repurchase programme
08/12NOVO NORDISK : Trading in Novo Nordisk shares by board members, executives and a..
More news
Financials (DKK)
Sales 2019 120 B
EBIT 2019 52 399 M
Net income 2019 39 146 M
Finance 2019 12 374 M
Yield 2019 2,45%
P/E ratio 2019 20,9x
P/E ratio 2020 18,4x
EV / Sales2019 6,69x
EV / Sales2020 6,27x
Capitalization 816 B
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 354,82  DKK
Last Close Price 344,60  DKK
Spread / Highest target 30,6%
Spread / Average Target 2,97%
Spread / Lowest Target -35,3%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS15.68%121 415
JOHNSON & JOHNSON2.48%344 675
ROCHE HOLDING LTD.12.16%238 287
MERCK AND COMPANY12.09%219 296
NOVARTIS17.97%204 985
PFIZER-19.40%191 430